BiotechTube

ZD4054 Zibotentan + Paclitaxel + Carboplatin + Placebo

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy

Conditions

Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy

Trial Timeline

Jun 1, 2009 → Jun 1, 2011

NCT ID
NCT00929162

About ZD4054 Zibotentan + Paclitaxel + Carboplatin + Placebo

ZD4054 Zibotentan + Paclitaxel + Carboplatin + Placebo is a phase 2 stage product being developed by AstraZeneca for Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy. The current trial status is terminated. This product is registered under clinical trial identifier NCT00929162. Target conditions include Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy.

What happened to similar drugs?

18 of 20 similar drugs in Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy were approved

Approved (18) Terminated (1) Active (2)
✅ATG-FAstellas PharmaApproved
✅Clopidogrel + TicagrelorAstraZenecaApproved
✅OlaparibAstraZenecaApproved
✅BenralizumabAstraZenecaApproved
✅GefitinibAstraZenecaApproved
✅Imipenem + ImipenemMerckApproved
✅Cyclosporine - cyclosporine microemulsionNovartisApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00929162Phase 2Terminated

Competing Products

20 competing products in Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy

See all competitors
ProductCompanyStageHype Score
R744 + R744Chugai PharmaceuticalPhase 3
40
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
40
R744 + Epoetin betaChugai PharmaceuticalPhase 3
40
R744 + R744Chugai PharmaceuticalPhase 3
40
R744 + R744Chugai PharmaceuticalPhase 3
40
R744Chugai PharmaceuticalPhase 3
40
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
32
FK949EAstellas PharmaPhase 1
29
roxadustatAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
ASP8825Astellas PharmaPhase 1
29
ASP015KAstellas PharmaPhase 1
29
ASP7991Astellas PharmaPhase 1
29
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
40
ATG-FAstellas PharmaApproved
43
CelecoxibAstellas PharmaPre-clinical
26
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
FK949EAstellas PharmaPhase 1
29